Fresh off CG Oncology exit, ORI Capital raises $260M second fund
22 Feb 2024
Phase 3IPOFast TrackBreakthrough TherapyImmunotherapy
Flush with the success of portfolio company CG Oncology’s public debut, venture firm ORI Capital closed its second fund on Thursday at $260 million, exceeding its original target.
The firm is looking to invest in early-stage companies developing diagnostics, drug delivery solutions, and therapeutics in the cancer, metabolic disorders and neurodegenerative disease spaces.
In particular, ORI is eyeing next-generation small molecules, protein degraders, DNA and RNA therapies, immuno-oncology cell therapies, and synthetic biology.
The firm’s most recent exit may provide some insight into what technologies are on its radar. In January, CG Oncology raised a bumped-up $380-million IPO to progress its Phase III cancer programme to regulatory filings. Its oncolytic immunotherapy cretostimogene grenadenorepvec has fast-track and breakthrough therapy designations from the FDA to treat high-risk, Bacillus Calmette-Guérin-unresponsive non-muscle invasive bladder cancer. For more, see Vital Signs: CG Oncology breaks into the top ten.
AI on target
ORI said AI will also be a big factor for its second fund, both to find investment opportunities, and as a target for said investments.
The firm plans to use its ORIZON AI platform – which provides daily updates on more than 31,000 global healthcare companies, follows 62,000 key opinion leaders, and tracks the investment activities of 5000 fund managers – to source differentiated investments and partner with companies.
Companies with a smart combination of AI technology and science are also an attractive target for the firm.
“We are in a golden-era of innovation across the intersection of AI and biology, where technological breakthroughs are creating new approaches to diagnosing and treating disease,” said Simone Song, the firm’s founding partner. “We believe the current environment provides an attractive opportunity for investing in the next generation of leading biotech companies.”
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-Chat with Hiro
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.